Jeannet E. Canda, RN,MAED NDDU College of Nursing Fetal Medicine Gestational Trophoblastic Disease (GTD) is a relatively rare event with a calculated incidence of 1/714 live births.
There is evidence of ethnic variation in the incidence of GTD in the UK, with women from Asia having a higher incidence compared with non-Asian women (1/387 versus 1/752 live births).
This may under-represent the true incidence of the disease because of problems with reporting, particularly with regard to partial moles.
Fetal Medicine Hydatiform mole Invasive mole Choriocarcinoma Placental site trophoblastic tumor Partial Complete GESTATIONAL TROPHOBLASTIC DISEASE
Fetal Medicine Epidemiology
The incidence of molar pregnancy varies in different parts of the world.
Women of Asian origin: 1 in 550 to 1 in 600. Women of European origin: 1 in 1200 live births
Fetal Medicine
Age is probably the most important factor in the incidence of developing complete hydatidiform mole.
Where the incidence for women aged 25 to 29 is standardized as 1, the risk is
6 X in women who become pregnant under 15 years
411 X in patients who become pregnant over the age of 50
Epidemiology
Fetal Medicine North America and Europe: Partial mole 1/700 Complete mole 1/1500-2000
Asian Countries: Partial mole 1/120 Complete mole 1/350-500
HYDATIDIFORM MOLE Incidence Fetal Medicine 1. Maternal age > 40 years < 15 years
2. Paternal age > 45 years
3. Previous hydatidiform mole 1 st 1-2% 2 nd 15-28%
4. Vitamin A deficiency
HYDATIDIFORM MOLE Risk factors Fetal Medicine Background
Hydatidiform mole is subdivided into complete and partial mole based on genetic and histo-pathological features.
Complete moles are diploid andro-genetic in origin no evidence of fetal tissue.
Arise as a consequence of 1. duplication of the haploid sperm following fertilisation of an empty ovum ( diandry) 2. Some complete moles arise after dispermic fertilisation of an empty ovum. (dispermy)
Molar Pregnancy Complete Mole Fetal Medicine Empty ovum Empty ovum 46XX 46XX or 46XY 23X or Y 23X 23X Complete Mole (46XX diploid) Complete Mole (46XX or 46XY, diploid) A single sperm fertilizes an empty ovum, with duplication of the 23X haploid set of chromosomes, giving rise to a homozygous diploid complete mole. Two sperms with two independent haploid sets of chromosomes fertilize an empty ovum, producing a dyspermic complete mole with either 46XX or 46XY karyotype. COMPLETE MOLE Modified from Cheung, 1995 Fetal Medicine Complete molar pregnancy Complete hydatidiform mole forms a multivesicular mass with diffuse hydropic villi and a variable degree of trophoblastic proliferation.
There is usually no evidence of a foetus. This conceptus is diploid and androgenetic in origin.
The incidence of a GT Tumour is approximately 1000X more likely following a complete hydatidiform mole than after a full-term pregnancy. One possible explanation is that genomic imprinting plays a role in tumourigenesis since the complete mole is androgenetic in origin. Fetal Medicine Fetal Medicine Fetal Medicine Fetal Medicine Fetal Medicine
Triploid in origin with usually two sets of paternal haploid genes and one set of maternal haploid genes.
They occur, in almost all cases, following dispermic fertilisation of an ovum. There is usually evidence of a fetus or fetal red blood cells. In some cases failure of meiosis I or II in the ovum leads to Triploidy with 46 maternally derived chromosomes and 23 paternal
Partial Molar Pregnancy
Fetal Medicine 23X 23X Dyspermy 23X/23Y or 23X/23X 23Y Partial Mole (69XXY, or 69XXX, or 69XYY triploid) PARTIAL MOLE 23X 23X 23Y 69XXY Fertilization of a normal 23X haploid ovum by two sperms, producing a triploid partial mole with either 69XXY, 69XXX or 69XYY karyotype Modified from Cheung, 1995 Fetal Medicine Fetal or embryonic tissue absent present Hydatiform swelling of chorionic villi extensive focal Trophoblastic hyperplasia extensive focal Scalloping of chorionic villi absent present Trophoblastic stromal inclusions absent present Karyotype 46XX (90%); Triploid (69 XXY) 46XY (10%) Complete mole Partial mole Cohn DE, Herzog TJ. Curr Opin Oncol 2000 Sep; 12(5):492-6 FEATURES OF PARTIAL AND COMPLETE MOLE
Fetal Medicine Fetal Medicine
Persistent GTD The term persistent "gestational trophoblastic disease" is widely used to describe the situation where a woman has had a hydatidiform mole and still has persistently raised human chorionic gonadotrophin (hCG) estimations
Since in the majority of cases the disease either remits spontaneously or can be successfully treated without further pathological sampling, it is difficult to say exactly in what proportion of patients their hydatiform mole modulates to choriocarcinoma. This event probably happens in 3% to 5% of patients who have had a complete hydatidiform mole Fetal Medicine Gestational Trophoblastic Disease
Persistent GTD may develop 1. After a molar pregnancy, 2. After a non-molar pregnancy 3. After a live birth (~ 1/50 000)
Fetal Medicine Gestational Trophoblastic Tumours Overview
GTT are unique in cancer biology in that they follow 1. either a normal or abnormal pregnancy, 2. the tumours contain paternal genes and are therefore an allograft in the maternal host. Fetal Medicine Invasive Hydatidiform Mole Invasive hydatidiform mole (complete or partial) is common since molar trophoblast invades the myometrium in most cases.
Pathologically invasive hydatidiform mole can be diagnosed only when sufficient myometrium is made available to the pathologist either on curettings or by hysterectomy Fetal Medicine Invasive Hydatidiform Mole
An invasive mole retains hydropic villi, which penetrate the uterine wall. Can cause uterine rupture and can be life threatening. Hydropic villi may embolize to distant organs, but this tumor does not have metastatic potential. Cure is possible by hysterectomy or chemotherapy. Fetal Medicine Choriocarcinoma It is an unusual tumour in that it stimulates virtually no stromal reaction and is therefore essentially a mixture of haemorrhage and necrosis with tumour cells scattered within the mass.
Tumour cells can be scanty and present problems of pathological interpretation if the possibility of choriocarcinoma has not been raised.
The pathology of choriocarcinoma is reflected in its clinical behaviour with widespread intravascular dissemination to lungs, brain and other sites. Fetal Medicine Choriocarcinoma
Is a very aggressive malignant tumor and arises either from gestational chorionic epithelium or less frequently, from totipotential cells within gonads or elsewhere.
Incidence is 1/ 30,000 pregnancies in US.
More common in Asian and African countries. Fetal Medicine Choriocarcinoma
Most cases are discovered by the appearance of a bloody, brownish discharge, accompanied by a rising titer of HCG, particularly the beta subunit.
Usually appear as very hemorrhagic, necrotic masses within the uterus.
Widespread dissemination via blood, lung (50%), vagina (30-40%), brain, liver and kidney. Fetal Medicine Placental site trophoblastic tumours Placental site trophoblastic tumours are now recognised as a separate entity.
1. rare and 2. are composed mainly of cytotrophoblastic cells 3. tend to be locally invasive 4. less widely metastatic than choriocarcinoma
The optimal management of patients with placental site trophoblastic tumours is unclear. This is because (i) the tumours are rare and (ii) their biological behaviour does appear to be variable. Fetal Medicine
Where the disease is localised to the uterus, hysterectomy is the treatment of choice.
A small number of patients treated with intensive chemotherapy initially have achieved complete remission but the chemosensitivity of placental site trophoblastic tumours appears to be quite variable
Placental site trophoblastic tumours Fetal Medicine Clinical presentation
The most common presentation of a patient with a GTD is 1. vaginal bleeding towards the end of the first trimester of pregnancy. 2. nausea and vomiting and 3. uterus larger for dates than for a normal pregnancy.
Since the quantity of hCG produced by a normal pregnancy can vary over quite a wide range, the initial hCG estimation is not helpful in differentiating between a pregnancy and a hydatidiform mole. Fetal Medicine COMPLETE HYDATIFORM MOLE CLINICAL FEATURES Vaginal bleeding (anemia) 97% Excessive uterine size 50% Theco-lutein ovarian cysts 50% Preeclampsia 27% Hyperemesis 25% Hyperthyroidism 7% Trophoblastic embolization 2% (respiratory distress) Fetal Medicine The increasing performance of ultrasound examination, either routinely in the first trimester or for management of early pregnancy complications, allows evacuation of most pregnancies affected by hydatiform mole prior to development of the classic sonographic and pathological features. ULTRASOUND FINDINGS
Fetal Medicine Diagnosis of Gestational Trophoblastic Disease
Increasing use of ultrasound in early pregnancy has led to the earlier diagnosis of molar pregnancy.
The majority of histologically proven complete moles however are associated with an ultrasound diagnosis of delayed miscarriage or anembryonic pregnancy
The ultrasound features of a complete mole are reliable but the ultrasound diagnosis of a partial molar pregnancy is more complex. RCOG, February 2004
Fetal Medicine Management of GTD Suction curettage is the method of choice of evacuation for complete molar pregnancies.
Because of the lack of fetal parts a suction catheter, up to a maximum of 12 mm, is usually sufficient to evacuate all complete molar pregnancies
Medical termination of complete molar pregnancies, including cervical preparation prior to suction evacuation, should be avoided where possible because of the potential to embolise and disseminate trophoblastic tissue through the venous system
Fetal Medicine In partial molar pregnancies where the size of the fetal parts deters the use of suction curettage, medical termination can be used.
These women may be at an increased risk of requiring treatment for persistent trophoblastic neoplasia, although the proportion of women with partial molar pregnancies needing chemotherapy is low (0.5%)
Management of GTD Fetal Medicine Gestational Tropholastic Neoplasia- Requirement for diagnosis 1. 4 or more values of hCG plateau over ay least 3 weeks 2. A rise of hCG of 10% or greater for > 3 values over at least 2 weeks 3. Presence of Choriocarcinoma 4. Persistence of hCG 6 months after mole evacuation Fetal Medicine Women scoring >7 (high risk) receive combination chemotherapy.
IV Etoposide, Methotrexate, Actinomycin D for 2 days followed by Cyclophosphamide and Vincristine (Oncovin) (EMA-CO) one week later. The course is then repeated after six days. Charing Cross Hospital, London
Treatment of persistent GTD Fetal Medicine Future pregnancy
Women should be advised not to conceive until their hCG levels have been normal for six months.
Women who undergo chemotherapy are advised not to conceive for one year after completion of treatment
Risk of a further molar pregnancy is low (~ 2%) >98% of women who become pregnant following a molar pregnancy will not have a further mole or be at increased risk of obstetric complications. If a further molar pregnancy does occur, in 6880% of cases it will be of the same histological type
Fetal Medicine Follow-up and Fertility after Chemotherapy Approximately 90% of patients who want to become pregnant following chemotherapy have succeeded and there is no evidence of increase in foetal abnormalities.
Occasionally a G.T.T. can occur or recur after a subsequent normal pregnancy This emphasises the importance of reconfirming that hCG levels return to normal after any subsequent pregnancy in a woman who has had a trophoblastic disease event Fetal Medicine
Contraception and hormone replacement therapy
The COC-pill, if taken while hCG levels are raised, may increase the need for treatment.
However, it can be used safely after the hCG levels have returned to normal. Other forms of hormonal contraception do not appear to be linked to an increased need for treatment.
The small potential risk of using emergency hormonal contraception, in women with raised hCG levels, is outweighed by the potential risk of pregnancy to the woman.
Hormone replacement therapy may be used safely once hCG levels have returned to normal.
Fetal Medicine Survival
The overall survival in the Charing Cross series, with a maximum follow-up of 15 years is ~ 94% Fetal Medicine The successful outcome in patients with GTT depends on several factors:- (i) Need for a national registration scheme of patients at risk of developing a GTT (ii) The ability to monitor the disease and its response to treatment with serial hCG estimations. (iii) The intrinsic biological property of GTT in being inherently very sensitive to a range of chemotherapeutic agents. Survival